Page 345 - Glucose Monitoring Devices

352 CHAPTER 16 The dawn of automated insulin delivery

[62] Ly TT, Breton MD, Keith-Hynes P, De Salvo D, Clinton P, Benassi K, et al. Overnight
glucose control with an automated, unified safety system in children and adolescents
with type 1 diabetes at diabetes camp. Diabetes Care 2014;37(8):2310e6.
[63] Ly TT, Buckingham BA, DeSalvo DJ, Shanmugham S, Satin-Smith M, DeBoer MD,
et al. Day-and-Night closed-loop control using the unified safety system in adolescents
with type 1 diabetes at camp. Diabetes Care 2016;39(8):e106e7.
[64] Ly TT, Keenan DB, Roy A, Han J, Grosman B, Cantwell M, et al. Automated overnight
closed-loop control using a proportional-integral-derivative algorithm with insulin
feedback in children and adolescents with type 1 diabetes at diabetes camp. Diabetes
Technology and Therapeutics 2016;18(6):377e84.
[65] Ly TT, Roy A, Grosman B, Shin J, Campbell A, Monirabbasi S, et al. Day and night
closed-loop control using the integrated Medtronic hybrid closed-loop system in type 1
diabetes at diabetes camp. Diabetes Care 2015;38(7):1205e11.
[66] Phillip M, Battelino T, Atlas E, Kordonouri O, Bratina N, Miller S, et al. Nocturnal
glucose control with an artificial pancreas at a diabetes camp. New England Journal
of Medicine 2013;368(9):824e33.
[67] Russell SJ, Hillard MA, Balliro C, Magyar KL, Selagamsetty R, Sinha M, et al. Day
and night glycaemic control with a bionic pancreas versus conventional insulin pump
therapy in preadolescent children with type 1 diabetes: a randomised crossover trial.
The Lancet Diabetes and Endocrinology 2016;4(3):233e43.
[68] Breton MD, Chernavvsky DR, Forlenza GP, DeBoer MD, Robic J, Wadwa RP, et al.
Closed-loop control during intense prolonged outdoor exercise in adolescents with
type 1 diabetes: the artificial pancreas Ski study. Diabetes Care 2017;40(12):1644e50.
[69] Haidar A, Legault L, Matteau-Pelletier L, Messier V, Dallaire M, Ladouceur M, et al.
Outpatient overnight glucose control with dual-hormone artificial pancreas, single-
hormone artificial pancreas, or conventional insulin pump therapy in children and ad-
olescents with type 1 diabetes: an open-label, randomised controlled trial. The lancet
Diabetes and endocrinology 2015;3(8):595e604.
[70] Russell SJ, El-Khatib FH, Sinha M, Magyar KL, McKeon K, Goergen LG, et al.
Outpatient glycemic control with a bionic pancreas in type 1 diabetes. New England
Journal of Medicine 2014;371(4):313e25.
[71] Brown SA, Kovatchev BP, Breton MD, Anderson SM, Keith-Hynes P, Patek SD, et al.
Multinight “bedside” closed-loop control for patients with type 1 diabetes. Diabetes
Technology and Therapeutics 2015;17(3):203e9.
[72] Kovatchev BP, Renard E, Cobelli C, Zisser HC, Keith-Hynes P, Anderson SM, et al.
Safety of outpatient closed-loop control: first randomized crossover trials of a wearable
artificial pancreas. Diabetes Care 2014;37(7):1789e96.
[73] Kovatchev BP, Renard E, Cobelli C, Zisser HC, Keith-Hynes P, Anderson SM, et al.
Feasibility of outpatient fully integrated closed-loop control first studies of wearable
artificial pancreas. Diabetes Care 2013;36(7):1851e8.
[74] Sharifi A, De Bock MI, Jayawardene D, Loh MM, Horsburgh JC, Berthold CL, et al.
Glycemia, treatment satisfaction, cognition, and sleep quality in adults and adolescents
with type 1 diabetes when using a closed-loop system overnight versus sensor-
augmented pump with low-glucose suspend function: a randomized crossover study.
Diabetes Technology and Therapeutics 2016;18(12):772e83.
[75] Haidar A, Rabasa-Lhoret R, Legault L, Lovblom LE, Rakheja R, Messier V, et al.
Single-and dual-hormone artificial pancreas for overnight glucose control in type 1
diabetes. The Journal of Clinical Endocrinology 2016;101(1):214e23.